<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-058184</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections</dc:title>
<dc:description xml:lang="en">Resistance to fosfomycin develops rapidly in experimental conditions, although despite its frequent use in UTI, resistance in E. coli, the main        uropathogen, is very low (1-3%), and has remained so for many years. The objective of this study was to ascertain whether E. coli fosfomycin-        resistant strains have less fitness than those that are fosfomycin-sensitive in competing, and would therefore tend to disappear in their        competition with fosfomycin-sensitive strains in the absence of antibiotics. Fosfomycin-resistant strains (n=11) with different phenotypes of        resistance to other antibiotics were used. All but one were lactose (+). Fosfomycin-susceptible strains (n=15) that had the same phenotypes        of resistance to other antibiotics as the resistant strains and which had the opposite pattern of lactose fermentation were also used. Thirty-three (33) competition experiments by pairs of strains were conducted in nutrient broth. Equal amounts of the strains were challenged (approx.        50% and approx. 50%) for 4 days, with a daily change to a new medium. Five differential counts were performed on days 0, 1, 2, 3        and 4. In 20 experiments (60.6%) there was a relative increase in the fosfomycin-sensitive strain. In 6 experiments (18.2%) there was a relative        increase in the fosfomycin-resistant strain. In 7 experiments (21.2%), on the fourth day none of the strains reached 60%. When the data        of the 26 (20+6) experiments in which there were changes were analyzed by the X2 test there was a statistically significant difference        (p=0.044). Resistance to fosfomycin could entail a biological cost (less fitness) for the majority of the E. coli strains assayed</dc:description>
<dc:creator>Tamayo, J</dc:creator>
<dc:creator>Alós, J. I</dc:creator>
<dc:creator>García-Peña, P</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La resistencia a la fosfomicina surge rápidamente en condiciones experimentales, pero aunque su uso es frecuente en las infecciones del tracto        urinario, la resistencia de Escherichia coli, el principal uropatógeno, es muy baja (1% a 3%) y ha permanecido así por muchos años. El objetivo        de este estudio fue evaluar si las cepas de E. coli resistentes a la fosfomicina tienen menos competitividad (fitness) que las sensibles, y        por tanto tenderían a desaparecer al competir con las cepas sensibles en ausencia de antibióticos. Se utilizaron cepas resistentes a la fosfomicina        (n=11) con diferentes fenotipos de resistencia a otros antibióticos, y cepas sensibles a la fosfomicina (n=15) con los mismos fenotipos        de resistencia al resto de los antibióticos que algunas de las cepas resistentes, pero con el patrón opuesto de fermentación de la lactosa.        Se realizaron 33 experimentos de competición por pares en caldo nutriente. Se utilizaron cantidades iguales de cada cepa (50%-50%) durante        cuatro días, con cambio diario a un nuevo medio. Se hicieron cinco recuentos diferenciales, los días 0, 1, 2, 3 y 4. En 20 experimentos        (60,6%) hubo un incremento relativo de la cepa sensible a la fosfomicina. En seis experimentos (18,2%) hubo un incremento relativo de la cepa        resistente a la fosfomicina. En siete experimentos (21,2%) ninguna cepa mostró un incremento relativo. Cuando los datos de los 26 experimentos        en que había cambios se analizaban por X2 había una diferencia estadísticamente significativa (p=0.044). La resistencia a la fosfomicina        puede suponer un coste de competitividad para la mayoría de las cepas de E. coli probadas</dc:description>
<dc:source>Rev Esp Quimioter;20(2): 211-215, jun.2007. ilus, tab</dc:source>
<dc:identifier>ibc-058184</dc:identifier>
<dc:title xml:lang="es">Coste biológico asociado a la resistencia a la fosfomicina en aislamientos de Escherichia coli de orina</dc:title>
<dc:subject>^d5016^s22001</dc:subject>
<dc:subject>^d14952^s22027</dc:subject>
<dc:subject>^d14952^s22057</dc:subject>
<dc:subject>^d5016^s22021</dc:subject>
<dc:subject>^d911^s22078</dc:subject>
<dc:subject>^d5712^s22078</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5712^s22050</dc:subject>
<dc:subject>^d19042</dc:subject>
<dc:subject>^d14956^s22046</dc:subject>
<dc:subject>^d911^s22050</dc:subject>
<dc:type>article</dc:type>
<dc:date>200706</dc:date>
</metadata>
</record>
</ibecs-document>
